Accessibility Menu
Dna X logo

Dna X(NASDAQ) SONM

Market Cap$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-67%
1 Month+3%
$3.23
-6.11%
-0.21Today
Dna X last closing stock price
MetricPriceDate
Last closeUSD 3.232026-08-21
Dna X stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.33%USD 3.492026-08-14
1 month+2.87%USD 3.142026-07-22
3 month-27.9%USD 4.482026-05-22
Year to date+2.54%USD 3.152025-12-31
1 year-67.36%USD 9.892025-08-21
3 year-96.83%USD 101.862023-08-22
5 year-99.54%USD 699.842021-08-20
Since inception-99.98%USD 19,781.982019-05-10

Dna X Financials at a Glance

Market Cap

$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-$27.91M

Net Income (TTM)

-$8.55M

EPS (TTM)

-$177.67

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.17 (Average)

Price

$3.23

Volume

14,856.923

Open

$3.33

Previous Close

$3.23

Daily Range

$3.20 - $3.36

52-Week Range

$2.52 - $16.97

Estimated Earnings Date

Nov 17, 2026

SONM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dna X

DNA X helps people trade cryptocurrencies online without holding their assets. Its platform lets users buy, sell, and automate crypto trades. The service aims to make trading easier for individuals worldwide.

Products and Services

  • Crypto Trading Platform: Lets users trade, swap, and automate cryptocurrency transactions; 100% of 2025 revenue from continuing operations.
  • Automated Strategy Tools: Users can create, test, and share trading strategies with public leaderboards.
  • Simulation Features: Allows users to practice trades and view top-performing strategies before risking real assets.
  • Planned Crypto Lending: Developing features for users to lend or borrow crypto for interest-like fees.
  • Legacy Rugged Devices: Sold rugged phones and hotspots until January 2026; now discontinued.

Growth and Expansion

  • Acquired DNA X, LLC and launched crypto trading platform in December 2025.
  • Sold legacy phone and hotspot business for $15M in January 2026.
  • Shifted focus to crypto trading, ending hardware operations in early 2026.
  • Plans to expand platform features and supported cryptocurrencies in 2026.

What Makes DNA X Stand Out

DNA X does not hold customer crypto, reducing some risks. Its platform offers low trading fees and tools for automated strategies. The company relies on organic growth and aims to attract users with educational features.

Five Things You Need to Know

  • Revenue was $16M in QQ3 2025, up 7.9% from QQ3 2024.
  • Operating loss was $4M in QQ3 2025, down from $2M in QQ3 2024.
  • Cash used in operations was $7M in QQ3 2025, down from $417K in QQ3 2024.
  • Legacy business contributed $56.9M in 2025 revenue before being sold.

Bottom Line

DNA X has shifted from hardware to focus on crypto trading. The company faces liquidity and competition challenges as it builds its new business model.

AI Generated • Apr 16, 2026

Industry

Technology Hardware, Storage and Peripherals

Sector

Information Technology

Employees

160

CEO

Michael C. Mulica, MBA

Website

www.sonimtech.com

Headquarters

San Diego, CA 92121, US

SONM Financials

Key Financial Metrics (TTM)

Gross Margin

48.85%

Operating Margin

15.10%

Net Income Margin

30.62%

Return on Equity

391.03%

Return on Capital

N/A

Return on Assets

-189.22%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.49M

Volume

14.86K

Avg. Volume

25.60K

Financials (TTM)

Gross Profit

-$13.64M

Operating Income

-$4.22M

EBITDA

-$2.65M

Operating Cash Flow

-$14.51M

Capital Expenditure

-$94.00K

Free Cash Flow

-$14.60M

Cash & ST Invst.

$900.00K

Total Debt

$2.40M

Dna X Performance Analysis

Dna X annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 69,828,00028.0%
20232023-12-31USD 93,632,00034.1%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Dna X sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3044.9%
Q42025-12-31-372.1%
Q12026-03-31100.0%
Q22026-06-30N/A
Dna X annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -87.77-88.1%
20232023-12-31USD -0.39-99.6%
20242024-12-31USD -128.3732917.2%
20252025-12-31USD -28.58-77.7%
Dna X sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-511.4%
Q42025-12-3185.9%
Q12026-03-31-972.1%
Q22026-06-3087.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$134.00K

-115.9%

Gross Margin

0.00%

N/A

Market Cap

$4.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.20M

N/A

Employees

4

N/A

Net Income

-$1.25M

+83.3%

EBITDA

-$1.10M

+82.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$900.00K

-55.1%

Total Debt

$2.40M

-17.7%

Accounts Receivable

$1.26M

-87.4%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$2.40M

-17.7%

Return on Assets

-1.89%

N/A

Return on Invested Capital

6.67%

N/A

Free Cash Flow

-$2.10M

+57.1%

Operating Cash Flow

-$2.00M

+59.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOSSOS Limited
$0.99+2.33%
GXAIGaxos.ai Inc.
$0.88+1.48%
BHATFujian Blue Hat Interactive Entertainment Technology Ltd.
$0.68+349.70%
NVNINvni Group Limited Ordinary Shares
$1.04+0.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About SONM

What is the current price of Dna X?

Dna X is trading at $3.23 per share.

What is the 52-week range for Dna X?

Over the past 52 weeks, Dna X has traded between $2.52 and $16.97.

How much debt does Dna X have?

As of the most recent reporting period, Dna X reported total debt of $3.20M.

How much cash does Dna X have on hand?

Dna X reported $900.00K in cash and cash equivalents in its most recent financial results.

What is Dna X’s dividend yield?

Dna X does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services